What Happened? Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) fell 10.9% in the afternoon session after the company reported disappointing fourth-quarter results: EPS missed ...

Biotechnology company United Therapeutics (NASDAQ:UTHR) in Q4 CY2024, with sales up 19.7% year on year to $735.9 million. Its GAAP profit of $6.19 per share was 1.2% below analysts’ consensus ...

United Therapeutics is highly undervalued with a P/E of 16x and EV/EBITDA of 8.64x, compared to sector medians of 28x and 15.15x, respectively. The company shows strong revenue growth, driven by ...

UNITED THERAPEUTICS ($UTHR) is expected to release its quarterly earnings data on Wednesday, February 26th before market open, per Finnhub. Analysts are expecting ...

United Therapeutics (UTHR) shares soared 4.9% in the last trading session to close at $370.74. The move was backed by solid volume with far more shares changing hands than in a normal session.

United Therapeutics is down 11.5% since the beginning of the year, and at $318.89 per share, it is trading 22.2% below its 52-week high of $410 from November 2024.

Biotechnology company United Therapeutics (NASDAQ:UTHR) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 19.7% year on year to $735.9 million. Its GAAP profit of $6.19 per ...